Antitumor activity of extract against benzo(a)pyrene-induced lung tumorigenesis in Swiss Albino mice.

Sherien K Hassan, Amria M Mousa, Nermin M El-Sammad, Abeer H Abdel-Halim, Wagdy K B Khalil, Elsayed A Elsayed, Nayera Anwar, Michael W Linscheid, Eman S Moustafa, Amani N Hashim, Mahmoud Nawwar
Author Information
  1. Sherien K Hassan: Department of Biochemistry, National Research Centre, Dokki, Cairo, Egypt.
  2. Amria M Mousa: Department of Biochemistry, National Research Centre, Dokki, Cairo, Egypt.
  3. Nermin M El-Sammad: Department of Biochemistry, National Research Centre, Dokki, Cairo, Egypt.
  4. Abeer H Abdel-Halim: Department of Biochemistry, National Research Centre, Dokki, Cairo, Egypt.
  5. Wagdy K B Khalil: Department of Cell Biology, National Research Centre, Dokki, Cairo, Egypt.
  6. Elsayed A Elsayed: Bioproducts Research Chair, Zoology Department, College of Science, King Saud University, Riyadh, Saudi Arabia.
  7. Nayera Anwar: Department of Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
  8. Michael W Linscheid: Laboratory of Applied Analytical and Environmental Chemistry, Humboldt-University, Berlin, Germany.
  9. Eman S Moustafa: October University of Modern Sciences and Arts, 6th October City, Egypt.
  10. Amani N Hashim: Department of Phytochemistry and Plant Systematics, National Research Centre, Cairo, Egypt.
  11. Mahmoud Nawwar: Department of Phytochemistry and Plant Systematics, National Research Centre, Cairo, Egypt.

Abstract

Lung cancer has one of the highest mortality rates among various types of cancer and is the most frequent cancer in the world. The incidence of lung cancer is increasing rapidly, in parallel with an increased incidence of smoking. Effective chemoprevention may be an alternative strategy to control the incidence of lung cancer. Thus, the objective of current work was to ascertain the possible preventive and therapeutic efficacies of extract in a mouse model of lung tumorigenesis and its cytotoxicity toward the A549 human lung cancer cell line. Lung tumorigenesis was induced by the oral administration of benzo(a)pyrene (50 mg/kg b.w.) twice per week to Swiss albino mice for 4 weeks. Benzo(a)pyrene-treated mice were orally administered (300 mg/kg body weight, 5 days/week) for 2 weeks before or 9 weeks after the first benzo(a)pyrene dose, for a total of 21 weeks. At the end of the administration period, various parameters were measured in the serum and lung tissues. The results revealed that the oral administration of benzo(a)pyrene resulted in increases in relative lung weight, serum levels of tumor markers (ADA, AHH, and LDH), and the inflammatory marker NF-κB, and a decreased total antioxidant capacity compared with the control. In addition, decreased levels of enzymatic and non-enzymatic antioxidants, with a concomitant increase in lipid peroxidation, metalloproteinases (MMP-2 and MMP-12), and the angiogenic marker VEGF were detected in lung tissues. Moreover, benzo(a)pyrene administration induced the upregulation of PKCα, COX-2, and Bcl-2 expression, with the downregulation of BAX and caspase-3 expression. treatment alleviated all alterations in these parameters, which was further confirmed by the histopathological analysis of lung tissues. The findings of the current work provide the first verification of the preventive and therapeutic potentials of extract against benzo(a)pyrene-induced lung tumorigenesis in mice.

Keywords

References

  1. Molecules. 2013 Dec 20;19(1):78-101 [PMID: 24362627]
  2. Saudi J Biol Sci. 2013 Apr;20(2):131-9 [PMID: 23961228]
  3. Virus Res. 2013 May;173(2):426-30 [PMID: 23416147]
  4. Front Immunol. 2012 Aug 27;3:265 [PMID: 22969765]
  5. Biomed Pharmacother. 2016 Aug;82:568-77 [PMID: 27470398]
  6. Toxicol Mech Methods. 2012 Jan;22(1):74-80 [PMID: 21859361]
  7. Nutrients. 2018 Nov 02;10(11):null [PMID: 30400131]
  8. BMC Cancer. 2008 Jul 31;8:218 [PMID: 18671849]
  9. Mol Biol Rep. 2012 Dec;39(12):10355-60 [PMID: 23053939]
  10. Trends Pharmacol Sci. 2007 Apr;28(4):162-5 [PMID: 17331592]
  11. Expert Rev Clin Immunol. 2009 Mar;5(2):145-65 [PMID: 20477063]
  12. Toxicol Rep. 2019 Aug 01;6:788-794 [PMID: 31440455]
  13. Toxicol Rep. 2019 Jul 18;6:703-711 [PMID: 31372348]
  14. Exp Lung Res. 2010 Nov;36(9):548-57 [PMID: 20815658]
  15. Nutr J. 2016 Dec 1;15(1):99 [PMID: 27903278]
  16. Clin Biochem. 2001 May;34(3):251-4 [PMID: 11408025]
  17. PLoS One. 2013 Dec 23;8(12):e84934 [PMID: 24376856]
  18. IUBMB Life. 2013 Nov;65(11):904-10 [PMID: 24265197]
  19. Pharmacol Rep. 2015 Oct;67(5):996-1009 [PMID: 26398396]
  20. Toxicol In Vitro. 2014 Aug;28(5):1026-35 [PMID: 24759803]
  21. Am J Physiol. 1999 Feb;276(2):L269-79 [PMID: 9950889]
  22. Asian Cardiovasc Thorac Ann. 2014 Mar;22(3):315-8 [PMID: 24585908]
  23. J Cancer Res Ther. 2014 Oct-Dec;10(4):1033-9 [PMID: 25579550]
  24. J Pharmacopuncture. 2014 Jun;17(2):7-17 [PMID: 25780694]
  25. Chem Res Toxicol. 2015 Aug 17;28(8):1616-26 [PMID: 26158771]
  26. Toxicol Rep. 2018 Jun 05;5:714-722 [PMID: 29984187]
  27. Nat Med. 2010 Feb;16(2):219-23 [PMID: 20081861]
  28. Matrix Biol. 2015 May-Jul;44-46:94-112 [PMID: 25912949]
  29. Toxicol Rep. 2014 May 16;1:114-121 [PMID: 28962232]
  30. Nutr Cancer. 2012;64(2):300-6 [PMID: 22243054]
  31. Pharmazie. 2016 Mar;71(3):162-8 [PMID: 27183713]
  32. J Pharmacopuncture. 2015 Jun;18(2):19-25 [PMID: 26120484]
  33. Acta Med Okayama. 2012;66(3):245-51 [PMID: 22729105]
  34. Cell Death Differ. 2009 Jul;16(7):935-8 [PMID: 19528949]
  35. Toxicol Sci. 2015 May;145(1):5-15 [PMID: 25911656]
  36. Biomed Res Int. 2014;2014:150845 [PMID: 25013758]
  37. Basic Clin Pharmacol Toxicol. 2006 Jun;98(6):593-8 [PMID: 16700823]
  38. Am J Reprod Immunol. 2007 Feb;57(2):93-107 [PMID: 17217363]
  39. Toxicol Rep. 2019 May 06;6:416-425 [PMID: 31193041]
  40. Mol Cell Biochem. 2006 Jul;287(1-2):127-35 [PMID: 16685462]
  41. Anticancer Agents Med Chem. 2012 Jul;12(6):565-79 [PMID: 22263788]
  42. Pharmazie. 2018 Apr 2;73(4):241-243 [PMID: 29609693]
  43. Int J Biol Sci. 2015 Jul 16;11(9):1100-12 [PMID: 26221076]
  44. Ann Biol Clin (Paris). 1998 May-Jun;56(3):305-19 [PMID: 9754263]
  45. Eur J Pharmacol. 2017 Oct 5;812:189-195 [PMID: 28684234]
  46. J Enzyme Inhib Med Chem. 2016;31(sup1):177-183 [PMID: 27028474]
  47. Pharmacol Rep. 2016 Apr;68(2):310-8 [PMID: 26922533]
  48. J Lab Clin Med. 1963 May;61:882-8 [PMID: 13967893]
  49. Toxicol Rep. 2019 Aug 16;6:875-888 [PMID: 31516840]
  50. Evid Based Complement Alternat Med. 2011;2011:591356 [PMID: 21792362]
  51. Biochem Pharmacol. 2006 Nov 30;72(11):1605-21 [PMID: 16889756]
  52. Mol Cell Biochem. 2012 Apr;363(1-2):335-45 [PMID: 22187222]
  53. Carcinogenesis. 2017 Aug 1;38(8):766-780 [PMID: 28637319]
  54. Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [PMID: 18440219]
  55. Int Immunopharmacol. 2013 Oct;17(2):254-9 [PMID: 23747734]
  56. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):16-26 [PMID: 12063165]
  57. Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1791-806 [PMID: 16987032]
  58. Mol Oncol. 2012 Aug;6(4):405-17 [PMID: 22507634]
  59. Indian J Urol. 2013 Jul;29(3):177-83 [PMID: 24082436]
  60. Mol Cell Biochem. 2009 Nov;331(1-2):135-43 [PMID: 19449198]
  61. Free Radic Biol Med. 2010 Dec 1;49(11):1603-16 [PMID: 20840865]
  62. BMC Cancer. 2013 Mar 27;13:158 [PMID: 23530866]
  63. J Histochem Cytochem. 2004 Jun;52(6):711-22 [PMID: 15150280]
  64. Cell Metab. 2014 May 6;19(5):795-809 [PMID: 24726384]
  65. Environ Toxicol Pharmacol. 2013 Sep;36(2):403-410 [PMID: 23764461]
  66. Oncogene. 2014 Nov 6;33(45):5225-37 [PMID: 24336328]
  67. Mol Cell Biochem. 2015 Feb;400(1-2):51-6 [PMID: 25359171]
  68. Toxicol Rep. 2019 Jun 15;6:556-563 [PMID: 31249789]
  69. Front Microbiol. 2015 Jun 02;6:550 [PMID: 26082767]
  70. CA Cancer J Clin. 2018 Nov;68(6):394-424 [PMID: 30207593]
  71. Asian Pac J Cancer Prev. 2015;16(11):4671-5 [PMID: 26107222]
  72. Arh Hig Rada Toksikol. 2011 Jun;62(2):121-9 [PMID: 21705299]
  73. Methods Enzymol. 1984;105:121-6 [PMID: 6727660]
  74. Eur J Med Chem. 2017 Dec 15;142:213-228 [PMID: 28793973]
  75. Int J Mol Sci. 2019 Mar 01;20(5):null [PMID: 30823649]
  76. Risk Anal. 2012 Jul;32 Suppl 1:S69-84 [PMID: 22882894]
  77. Cancer Res. 2006 Jan 1;66(1):581-7 [PMID: 16397275]
  78. Basic Clin Pharmacol Toxicol. 2009 May;104(5):360-5 [PMID: 19413655]

Word Cloud

Created with Highcharts 10.0.0lungcancerbenzotumorigenesispyreneadministrationmiceweeksLungincidenceextracttissuesvariouscontrolcurrentworkpreventivetherapeuticinducedoralSwissBenzoweightfirsttotalparametersserumlevelsmarkerdecreasedexpressionpyrene-inducedonehighestmortalityratesamongtypesfrequentworldincreasingrapidlyparallelincreasedsmokingEffectivechemopreventionmayalternativestrategyThusobjectiveascertainpossibleefficaciesmousemodelcytotoxicitytowardA549humancellline50 mg/kgbwtwiceperweekalbino4pyrene-treatedorallyadministered300 mg/kgbody5days/week29dose21endperiodmeasuredresultsrevealedresultedincreasesrelativetumormarkersADAAHHLDHinflammatoryNF-κBantioxidantcapacitycomparedadditionenzymaticnon-enzymaticantioxidantsconcomitantincreaselipidperoxidationmetalloproteinasesMMP-2MMP-12angiogenicVEGFdetectedMoreoverupregulationPKCαCOX-2Bcl-2downregulationBAXcaspase-3treatmentalleviatedalterationsconfirmedhistopathologicalanalysisfindingsprovideverificationpotentialsAntitumoractivityAlbinoCupheaigneaPlantphenolics

Similar Articles

Cited By